Basic Information | Post buying leads | Suppliers |
Name |
Metolazone |
EINECS | 241-539-3 |
CAS No. | 17560-51-9 | Density | 1.4 g/cm3 |
PSA | 100.88000 | LogP | 4.69820 |
Solubility | 60.3mg/L(25 oC) | Melting Point |
252-254°C |
Formula | C16H16ClN3O3S | Boiling Point | 613.6 °C at 760 mmHg |
Molecular Weight | 365.84 | Flash Point | 324.9 °C |
Transport Information | N/A | Appearance | Crystalline solid |
Safety | Risk Codes | N/A | |
Molecular Structure | Hazard Symbols | N/A | |
Synonyms |
Metenix;Diulo;6-Quinazolinesulfonamide,7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl- (8CI);2-Methyl-3-(o-tolyl)-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone;Metozalone;Mykrox;Normelan;Oldren;SR 720-22;Xuret;Zaroxolyn; |
Molecular Structure:
Molecular Formula: C16H16ClN3O3S
Molecular Weight: 365.8345
IUPAC Name: 7-Chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
Synonyms of Zaroxolyn (CAS NO.17560-51-9): 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone ; 5-25-09-00212 (Beilstein Handbook Reference) ; 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- ; 6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl- ; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide ; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide ; BRN 0965506 ; Diulo ; EINECS 241-539-3 ; HSDB 3367 ; Metalozone ; Metenix ; Metolazona ; Metolazone ; Metolazonum ; Metolazonum [INN-Latin] ; Microx ; Mykrox ; Oldren ; SR 720-22 ; UNII-TZ7V40X7VX
CAS NO: 17560-51-9
Classification Code: Antihypertensive ; Antihypertensive agents ; Cardiovascular Agents ; Diuretic ; Diuretics ; Drug / Therapeutic Agent ; Human Data ; Natriuretic Agents ; Reproductive Effect
Melting point: 252-254°C
Index of Refraction: 1.629
Molar Refractivity: 92.81 cm3
Molar Volume: 261.2 cm3
Surface Tension: 53.7 dyne/cm
Density: 1.4 g/cm3
Flash Point: 324.9 °C
Enthalpy of Vaporization: 91.06 kJ/mol
Boiling Point: 613.6 °C at 760 mmHg
Vapour Pressure: 5.43E-15 mmHg at 25°C
Zaroxolyn (CAS NO.17560-51-9) is used as a diruetic and an antihypertensive.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
man | TDLo | oral | 2mg/kg/2W-I (2mg/kg) | VASCULAR: STRICTIRA; CJAMGES OM VESSE;S | Postgraduate Medical Journal. Vol. 67, Pg. 860, 1991. |
mouse | LD50 | intraperitoneal | > 1500mg/kg (1500mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | United States Patent Document. Vol. #3360518, |
mouse | LD50 | oral | > 5gm/kg (5000mg/kg) | United States Patent Document. Vol. #3360518, | |
mouse | LD50 | subcutaneous | > 5gm/kg (5000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. | |
rat | LD50 | intraperitoneal | > 5gm/kg (5000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. | |
rat | LD50 | oral | > 5gm/kg (5000mg/kg) | Drugs in Japan Vol. 6, Pg. APP-20, 1982. | |
rat | LD50 | subcutaneous | > 5gm/kg (5000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. | |
women | TDLo | oral | 150ug/kg (0.15mg/kg) | BEHAVIORAL: GENERAL ANESTHETIC BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | British Medical Journal. Vol. 1, Pg. 1381, 1976. |
Human systemic effects by ingestion: general anesthesia, convulsions, and muscle contractions. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits Cl−, SOx, and NOx
RTECS of Zaroxolyn (CAS NO.17560-51-9): VA1700000